Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupando's clinical trial of its lead immunotherapy candidate, KUP-101. The trial will assess serial circulating tumor DNA (ctDNA) dynamics as part of treatment response monitoring. Patients with advanced tumors across multiple skin cancers will be treated with KUP-101 and Latitude MRD testing will be performed at multiple timepoints. To evaluate molecular response in this setting, the Latitude test is well suited to assess treatment response in the trial. View source version on businesswire.com: https://www.businesswire.com/news/home/20260812873623/en/Contacts:Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.comMedia: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com